© 2004 European Society for Medical Oncology
Review |
Palliative chemotherapy for advanced gastric cancer
1 Department of Internal Medicine I, Division of Oncology and 2 Center of Excellence in Clinical and Experimental Oncology (CLEXO), University of Vienna, Vienna, Austria
* Correspondence to: Dr M. Hejna, Department of Internal Medicine I, Division of Oncology, Waehringer Guertel 18–20, A-1090 Vienna, University of Vienna, Austria. Email: michael.hejna{at}meduniwien.ac.at
Background: More than two-thirds of patients diagnosed with gastric cancer will have unresectable disease. They present a difficult problem to clinicians as to whether to choose a strictly supportive approach or expose patients to the side-effects of a potentially ineffective treatment. The objective of this article is to review the clinical trials utilizing cytotoxic chemotherapy in patients with advanced gastric cancer.
Methods: A computerized (Medline) search was carried out to identify papers published on this topic between 1966 and 2003. Only articles with an English abstract were reviewed, and studies only presented in abstract form were not included in the analysis.
Results: A total of 101 trials were subsequently identified. Four randomized trials compared palliative chemotherapy with best supportive care in 174 patients with advanced gastric cancer. Effectiveness and side-effects were evaluated in 73 phase II studies and 24 randomized phase III trials.
Conclusion: Analysis of results shows chemotherapy to be superior to best supportive care alone. Combination chemotherapy compared with monochemotherapy is associated with significantly higher overall (complete plus partial) response rates but nevertheless results in similar survival. ECF (epirubicin, cisplatin and 5-fluorouracil) currently represents one of the most effective regimens for advanced gastric cancer, whereas among the newer combinations, irinotecan- or taxane-based regimens have also given promising results. In patients with a poor performance status, consideration could be given to leucovorin-modulated 5-fluorouracil alone. Prognosis for the majority of patients, however, remains poor, as increases in survival were moderate at best.
Key words: chemotherapy, gastric cancer, palliative treatment, review
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. OBA, M. KOBAYASHI, T. MATSUI, Y. KODERA, and J. SAKAMOTO Individual Patient Based Meta-analysis of Lentinan for Unresectable/Recurrent Gastric Cancer Anticancer Res, July 1, 2009; 29(7): 2739 - 2745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Goekkurt, S.-E. Al-Batran, J. T. Hartmann, U. Mogck, G. Schuch, M. Kramer, E. Jaeger, C. Bokemeyer, G. Ehninger, and J. Stoehlmacher Pharmacogenetic Analyses of a Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil and Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie J. Clin. Oncol., June 10, 2009; 27(17): 2863 - 2873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. KONISHI, S. KIKUCHI, T. OCHIAI, H. IKOMA, T. KUBOTA, D. ICHIKAWA, H. FUJIWARA, K. OKAMOTO, C. SAKAKURA, T. SONOYAMA, et al. Latrunculin A Has a Strong Anticancer Effect in a Peritoneal Dissemination Model of Human Gastric Cancer in Mice Anticancer Res, June 1, 2009; 29(6): 2091 - 2097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Goekkurt, S.-E. Al-Batran, U. Mogck, C. Pauligk, J. T. Hartmann, M. Kramer, E. Jaeger, G. Ehninger, and J. Stoehlmacher Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Ann. Onc., March 1, 2009; 20(3): 481 - 485. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Aykan and E. Idelevich The role of UFT in advanced gastric cancer Ann. Onc., June 1, 2008; 19(6): 1045 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. Oh, H.-C. Kwon, S. Lee, D. M. Lee, H. S. Yoo, S.-H. Kim, J. S. Jang, M. C. Kim, J.-S. Jeong, and H.-J. Kim A Phase II Study of Oxaliplatin with Low-dose Leucovorin and Bolus and Continuous Infusion 5-Fluorouracil (Modified FOLFOX-4) for Gastric Cancer Patients with Malignant Ascites Jpn. J. Clin. Oncol., December 1, 2007; 37(12): 930 - 935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Wagner, W. Grothe, J. Haerting, G. Kleber, A. Grothey, and W. E. Fleig Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data J. Clin. Oncol., June 20, 2006; 24(18): 2903 - 2909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ruzzo, F. Graziano, K. Kawakami, G. Watanabe, D. Santini, V. Catalano, R. Bisonni, E. Canestrari, R. Ficarelli, E. T. Menichetti, et al. Pharmacogenetic Profiling and Clinical Outcome of Patients With Advanced Gastric Cancer Treated With Palliative Chemotherapy J. Clin. Oncol., April 20, 2006; 24(12): 1883 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Di Lauro, F. Belli, M. G. Arena, S. Carpano, G. Paoletti, D. Giannarelli, and M. Lopez Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer Ann. Onc., September 1, 2005; 16(9): 1498 - 1502. [Abstract] [Full Text] [PDF]
|
|